Crossmark

Potent anti-myeloma efficacy of dendritic cell therapy in combination with pomalidomide and programmed death-ligand 1 blockade in a preclinical model of multiple myeloma

Crossref DOI link: https://doi.org/10.1007/s00262-020-02654-0

Published Online: 2020-07-04

Published Print: 2021-01

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Chu, Tan-Huy

Vo, Manh-Cuong

Park, Hye-Seong

Lakshmi, Thangaraj Jaya

Jung, Sung-Hoon

Kim, Hyeoung-Joon

Lee, Je-Jung http://orcid.org/0000-0002-4635-5697
Funding

Funding for this research was provided by:

National Research Foundation of Korea (2018R1A5A2024181, NRF-2018R1C1B5041536)
License Information

Text and Data Mining valid from 2020-07-04

Version of Record valid from 2020-07-04
More Information

Article History

Received: 28 February 2020

Accepted: 25 June 2020

First Online: 4 July 2020

Compliance with ethical standards

:

: The authors declare no conflicts of interest.

Document is current

Any future updates will be listed below